

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/819,561	03/27/2001	Larry L. Hood	155694-0054	2600
1622 7	590 05/02/2005		EXAMINER	
IRELL & MANELLA LLP			SHAY, DAVID M	
840 NEWPOR' SUITE 400	T CENTER DRIVE		ART UNIT	PAPER NUMBER
NEWPORT BEACH, CA 92660			3739	
			DATE MAIL ED: 05/02/2004	•

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	_			
	09/819,561	HOOD, LARRY L.				
Office Action Summary	Examiner	Art Unit				
	david shay	3739				
The MAILING DATE of this communication	1	1				
Period for Reply	••	·				
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication of the period for reply specified above is less than thirty (30) days, and if NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by some any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event, however, may a n. a reply within the statutory minimum of thi eriod will apply and will expire SIX (6) MO tatute, cause the application to become A	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>I</u>	December 15, 2004.					
·_ ·	2b)⊠ This action is non-final.					
3) Since this application is in condition for all	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)	2 and 55-59 is/are withdrawn are rejected.	rom consideration.				
Application Papers						
9) The specification is objected to by the Exar	miner.					
10)☐ The drawing(s) filed on is/are: a)☐	accepted or b) □ objected to	by the Examiner.				
Applicant may not request that any objection to	the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the co	•					
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the application from the International But * See the attached detailed Office action for a	nents have been received. nents have been received in a priority documents have been ureau (PCT Rule 17.2(a)).	Application No n received in this National Stage				
Attachment(s)	∧ □	Summany (PTO 412)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-9483) Information Disclosure Statement(s) (PTO-1449 or PTO/SI Paper No(s)/Mail Date 	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application (PTO-152) 				

Applicant argues that the laser of Bille et al, which changes the tissue into a "semi-liquid"

state, does not denature the tissue. To delete this argument applicant has included a definition

garnered from the world-wide-web. This argument is not convincing. Firstly, there is no

showing that this is the definition that would have been ascribed to his term at the time the

invention was made. Secondly, there is no showing that a corneal surgeon would use this

definition. Further, Stedman's Medical Dictionary (copyright 1995) defines "denatured" as

"Made unnatural or changed from normal in any of its characteristics". Thus clearly the change

from the normal viscoelastic properties of the stromal tissue would qualify as being "denatured".

Applicant's theory regarding the permanence of the change in the corneal curvature imparted by

the method of Bille et al is noted, however unsupported opinions by applicant's representative

are insufficient to overcome the clear teaching of Bille et al.

Claims 55-58 are indefinite because the preamble recites a method, but they depend from

an apparatus claim (claim 52). For the purposes of examination, these claims will be treated as

depending from claim 53.

The text of those sections of Title 35, U.S. Code not included in this action can be found

in a prior Office action.

Claims 1, 2, 45-47, 51, 53 and 54 are rejected under 35 U.S.C. 102(b) as being clearly

anticipated by Bille et al.

Claims 1-3, 36-38, 40, 42, 45-47, 51, 53 and 54 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Spears et al.

Claims 1-4 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bille et al in combination with Knopp et al. Bille et al teaches denaturing tissue. Knopp et al disclose a medical system that can denature a comea comprising laser (item 87), a stepper motor (item 41), and a lens (items 17 and 23). It would have been obvious to employ the laser of Bille et al in the device of Knopp et al, since this provides recurvature without affecting surface tissue, as taught by Bille et al or to employ the focal point displacement mechanism of Knopp et al, since Bille et al provides no particulars of the mechanisms for moving the beam, thus producing a device such as claimed.

Claims 36-38 and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bille et al in combination with Klopotek. Bille et al teaches denaturing eye tissue. Klopotek teaches configuring the intensity of an incident laser beam. It would have been obvious to the artisan of ordinary skill to employ the laser of Bille et al in the device of Klopotek, since this provides a non destructive recurvature or to employ the intensity configuring mask of Klopotek in the device of Bille et al, since it will work equally well with any laser, thus producing a device such as claimed.

Claims 1, 40, 41, 45 and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Knopp et al in combination with Bille et al, as applied to claims 1-4 and 40 are above, and

Art Unit: 3739

further in view of L'Esperance Jr. L'Esperance Jr. teaches an ocular surgery device which provides for the movement of the beam focal point in a circular pattern about the cornea at a predetermined diameter. It would have been obvious to the artisan of ordinary skill to employ a scanner with a scan pattern as taught by L'Esperance, Jr., since this is a useful pattern for ophthalmic surgery and to produce the pattern with the diameter of 6-8 millimeters, since L'Esperance, Jr. says only that the distance needs to be "predetermined" and using a distance of 6-8 millimeters would place it outside of the optically used portion of the cornea, which will prevent visual distortions as is notorious in the art, thus producing a device such as claimed.

Claims 1, 40, 41, 45 and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Knopp et al in combination with Bille et al, as applied to claims 1-4 and 40 are above, and further in view of L'Esperance Jr. L'Esperance Jr. teaches an ocular surgery device which provides for the movement of the beam focal point in a circular pattern about the cornea at a predetermined diameter. It would have been obvious to the artisan of ordinary skill to employ a scanner with a scan pattern as taught by L'Esperance, Jr., since this is a useful pattern for ophthalmic surgery and to produce the pattern with the diameter of 6-8 millimeters, since L'Esperance, Jr. says only that the distance needs to be "predetermined" and using a distance of 6-8 millimeters would place it outside of the optically used portion of the cornea, which will prevent visual distortions as is notorious in the art, thus producing a device such as claimed.

Claims 37 and 42-44 are rejected under 35 U.S.C 103(a) as being unpatentable over Bille et al in combination with Klopotek as applied to claims 36-38 and 42 above, and further in view

Application/Control Number: 09/819,561

Art Unit: 3739

of L'Esperance, Jr. L'Esperance, Jr. teaches providing a circularly scanned spot, which

denatures tissue. Thus it would have been obvious to the artisan of ordinary skill to employ the

intensity modifier of Klopotek to produce the intensity pattern of the spot in the method of

L'Esperance, Jr. since the outputs of laser such as used by L'Esperance, Jr. have a non-uniform

intensity distribution, thus producing a method such as claimed.

Applicant's arguments filed December 15, 2004 have been fully considered but they are

not persuasive. The arguments are not convincing for the reasons set forth above.

Any inquiry concerning this communication should be directed to david shay at telephone

number 571-272-4773.

Shay/am

March 22, 2005

DAVID M. SHAY PRIMARY EXAMINER Page 5

GROUP 330